First Tracks reports positive Phase 1b celiac data, plans late-stage trial in 2027
The company also disclosed a $200 million private placement and pro forma cash of $343 million, as it moves ANB033 toward registrational studies.
SEC filing
3 stories
The company also disclosed a $200 million private placement and pro forma cash of $343 million, as it moves ANB033 toward registrational studies.
SEC filing
Kiniksa lifted its 2026 ARCALYST revenue outlook to $1.045-$1.050 billion and said pivotal Phase 3 data on KPL-387 are still expected in the second half of 2027.
SEC filing (6)
The San Diego biotech completed its previously announced stock sale on October 19, 2026 and signed a registration rights agreement with investors.
SEC filing (2)